Klaus-Henning K.
- Country
- Germany
- Department
- Klinik für Strahlentherapie
Research Overview
- Phase IIa Multicenter Study of Isotoxic Radiochemotherapy with Bevacizumab in IDH Wild-Type, MGMT Unmethylated Glioblastoma
- Evaluation of Durvalumab in Combination with Cisplatin, Carboplatin, and Etoposide with Radiotherapy in Extensive-Stage Small Cell Lung Cancer
- Efficacy of Pembrolizumab and Lenvatinib Maintenance Therapy Post-Chemoradiation in Locally Advanced PD-L1 Positive Head and Neck Squamous Cell Carcinoma
Data & Insights
Has run more than one trial at 6 of 21 partner sites.
Specializations
Head and Neck Oncology
The investigator specializes in treating locally advanced head and neck squamous cell carcinoma, with particular focus on combining immunotherapy approaches with conventional treatments.
- Immunotherapy integration
- Combination therapy strategies
- Post-chemoradiation treatment approaches
Expertise includes developing maintenance therapy protocols using targeted and immunotherapeutic agents.
Neuro-Oncology
The investigator focuses on advancing treatment strategies for glioblastoma, particularly exploring innovative approaches in radiation therapy and anti-angiogenic treatments.
- VEGF inhibition therapies
- Dose escalation protocols
- Survival outcome optimization
Specializes in developing protective strategies during intensive brain tumor treatments.
Thoracic Oncology
The investigator concentrates on treating extensive stage small cell lung cancer, incorporating novel combination approaches with immunotherapy and radiation treatment.
- Combined modality treatments
- Stereotactic radiotherapy
- Immunotherapy maintenance protocols
Expertise in integrating multiple treatment modalities for advanced thoracic malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.